Smita Nimkar MSc

CRS:

BJMC

Role:

Regulatory and Data Management

Position:

Regulatory Coordinator

Email:

nsmita13@gmail.com

Smita Nimkar is Regulatory Coordinator and IRB/EC Liaison for the clinical research site (CRS) at BJ Government Medical College (BJGMC) in Pune, India. The BJGMC CRS is part of the Baltimore-Washington-India Clinical Trials Unit (BWI-CTU)—which conducts clinical trials under the NIH ACTG and IMPAACT Trial Networks—along with the Johns Hopkins CRS (Baltimore, MD) and the Whitman Walker Health CRS (Washington, DC). She works with the India research team to ensure training on and compliance with scientific regulatory standards at all levels, assists with all submissions to IRBs including new protocols, progress reports, amendments, reviews, adverse event reports, and other assurance requirements. She is Vice Chair of the ACTG -Site Management Clinical Care Committee (SMCCC), ex member of IMPAACT Training and Education Committee, Life Member of the Forum for Ethics Review Committees in India, and member of Public Responsibility in Research (PRIM&R). Smita has worked in healthcare for more than 20 years, and her experience includes HIV/AIDS work, and clinical pathology, clinical research, contract research, and integrated research (Modern and Traditional) to develop new drugs and formulations from medicinal plants, She also has coordinated several research projects on communicable and non-communicable diseases. She is currently pursuing a PhD in health sciences.

  • Co-vice chair, Site Management and Clinical Care Committee (SMCCC)
  • Field Representative ACTG 5365, ACTG 5373, ACTG 5384
  • Nishi Suryavanshi, GauriRaval, Savita Kanade, Smita Nimkar, VaishaliNadgiri, PrassanaSahu, DeelipKadam, Sandhya Khadse, VidyaMave,, Nikhil Gupte, Amita Gupta, Anita Shankar, Challenges to disclosure of HIV status to perinatally infected children: A study of caregiver perspectives in Pune, India, Journal of Pediatric Infectious Diseases, Vol 9, No.2/2014

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5300B/I2003B/PHOENIX, Protecting Households On Exposure to...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...

Read More

Impact of Tuberculosis Infection on HIV-1 Antibody Response...

Study Objective: Compare longitudinal HIV-1 antibody responses among HIV-1 infected participants that either did or did not...

Read More

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

A5282: A Randomized, Phase II Trial to Compare an HPV...

The investigators are looking for a better way to prevent cervical cancer. This study is comparing two different methods to...

Read More

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More